Neurocrine Biosciences, Inc.
|
 | ||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
 |
return to message board, top of board |
Re: WorkingBased on first UCN2 phase II trial, It actually decrease creatine in heart failure population which is different from second trial population - ADHF. UCN2 would be very likely dead if we don't have a partnership in next 6-8 months
|
|||||||||||||||||||
|
|
return to message board, top of board |
| Msg # | Subject | Author | Recs | Date Posted |
| 33737 | Re: Working | phition42 | 0 | 7/1/2012 11:34:53 PM |
